Headline Expenditure Projections
- Pharmaceuticals : SGD990mn (US$790mn) in 2013 to SGD1.04bn (US$840mn) in 2014; +5.5% in local currency terms and +5.0% in US dollar terms. Forecast remained unchanged from Q214.
- Healthcare: SGD17.77bn (US$14.20bn) in 2013 to SGD19.66bn (US$15.83bn) in 2014; +11.0% in local currency terms and +9.1% in US dollar terms. Forecast remained broadly in line with Q214.
Singapore Pharmaceutical Risk/Reward Rating (RRR) score for Q314 is 62.1 out of the maximum 100 under our newly improved RRR system. The country scored above average for the majority of indicators and sub-indicators, including sector value growth, pensionable population and overall economic and political landscape. Consequently, with this high score, Singapore is ranked just slightly below other developed countries like Japan, Australia and South Korea, behind the highly attractive emerging Chinese market, and also behind Taiwan and Hong Kong.
- Key Trends And DevelopmentsIn April 2013 the Centre of Biomedical Ethics at the National University of Singapore's (NUS) Yong Loo Lin School of Medicine secured international recognition from the World Health Organization (WHO). The biomedical ethics centre will team up with four other collaborating centres to support the WHO in developing work in the field of...
The Singapore Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Singapore Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Singaporean pharmaceutical and healthcare industry.Key Benefits
CoverageBMI Industry View & Industry SWOT
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Singapore to test other views - a key input for successful budgeting and strategic business planning in the Singaporean pharmaceutical and healthcare market.
- Target business opportunities and risks in the Singaporean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Singapore.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.Company Profiles
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
BMI View: The considerable increase in the government's healthcare expenditure highlights Singapore's commitment to provide better, more affordable healthcare services for its population, particularly the elderly. The government's aim to further increase its expenditure to 40% o f the total health expenditure will bring about commercial benefits for healthcare players and pharmaceutical manufacturers , as it will potentially increase patient's access to healthcare. W e highlight a need for the country to expand community and home-based care so that hospitals will not be overburdened by patients who require long-term medical services.